| HOME >> BIOLOGY >> TECHNOLOGY |
The Platelet PGD Test is an easy-to-use, disposable device designed to detect the presence of a broad range of bacterial contaminants in platelets at a later phase in platelet unit life than current culture methods. Bacterial contamination in platelets and red blood cells represents the single greatest risk for lethal infections in transfusion medicine today. An estimated 10 million platelet units are transfused each year into patients in North America, Europe and Asia, and experts estimate that as many as 1 in every 2,000 units are contaminated with bacteria.
The Verax PGD Test is based on Verax Biomedical's proprietary Pan Genera(R) Detection technology, which targets common antigens found on the surface of all species of bacteria known to be pathogenic to humans.
For additional information, visit http://www.veraxbiomedical.com. Verax is located at 377 Plantation Street, Worcester, MA 01608. Tel.: 508-755-7029.
About Verax Biomedical, Inc.
Based in Worcester, Mass., Verax Biomedical is a leader in the
development of rapid tests designed to detect a broad range of bacterial
contaminants based upon its proprietary Pan Genera Detection (PGD)
technology. The first target application for its technology is to test for
the presence of bacterial contaminants in the blood supply. Bacterial
contaminants in platelets and red blood cells represent the greatest lethal
infectious risks in transfusion medicine today, and no rapid, simple
methods are presently available to effectively address this threat. Each
year an estimated 17 million patients receive more than 60 million units of
these individual blood components in North America, Europe and Asia
'/>"/>
| SOURCE Verax Biomedical Inc. Copyright©2007 PR Newswire. All rights reserved |